Antiepileptic drugs suppress seizure activity through modulation of ion channels, enhancement of GABAergic inhibition, or attenuation of glutamatergic excitation. Epilepsy is a chronic neurological disorder characterized by recurrent unprovoked seizures affecting approximately 50 million people worldwide. The goal of pharmacotherapy is complete seizure control without adverse effects, achievable in about two-thirds of patients with appropriate drug selection.
What Is Antiepileptic Drug Therapy?
Antiepileptic drugs (AEDs) are broadly classified as broad-spectrum agents effective against multiple seizure types or narrow-spectrum agents effective against focal seizures only. Seizure classification according to the International League Against Epilepsy guides drug selection. Therapy is initiated with monotherapy, and the choice of agent balances efficacy against tolerability, teratogenicity, and drug interaction potential.
Drug Classes and Mechanisms
Sodium channel blockers include phenytoin, carbamazepine, oxcarbazepine, lamotrigine, and lacosamide. These agents stabilize the inactive state of voltage-gated sodium channels, reducing repetitive neuronal firing. Calcium channel modulators include ethosuximide (T-type calcium channels in thalamic neurons, used for absence seizures) and gabapentin/pregabalin (alpha-2-delta subunit, used as adjunctive therapy). GABA enhancers include valproate (multiple mechanisms including GABA potentiation), benzodiazepines, barbiturates, tiagabine (GABA reuptake inhibitor), and vigabatrin (GABA transaminase inhibitor). SV2A modulators such as levetiracetam bind synaptic vesicle protein 2A, reducing neurotransmitter release through an incompletely understood mechanism. Topiramate has multiple actions including sodium channel blockade, GABA enhancement, and AMPA receptor antagonism.
Therapeutic Uses
Broad-spectrum AEDs (valproate, lamotrigine, levetiracetam, topiramate, zonisamide) are first-line for generalized epilepsies including absence, myoclonic, and tonic-clonic seizures. Narrow-spectrum agents (phenytoin, carbamazepine, oxcarbazepine, gabapentin, pregabalin, lacosamide) are indicated for focal (partial) seizures. Valproate is highly effective but carries teratogenic risk and metabolic side effects. Lamotrigine and levetiracetam are well tolerated with favorable interaction profiles. Ethosuximide is the drug of choice for childhood absence epilepsy.
Adverse Effects
Sodium channel blockers cause dose-related ataxia, dizziness, diplopia, and nystagmus. Carbamazepine and oxcarbazepine can cause hyponatremia. Lamotrigine requires slow titration to reduce the risk of Stevens-Johnson syndrome. Valproate is associated with weight gain, tremor, hepatotoxicity, polycystic ovary syndrome, and teratogenicity including neural tube defects. Levetiracetam may cause irritability, aggression, and other behavioral effects. Topiramate produces cognitive slowing, word-finding difficulty, renal calculi, and weight loss. Chronic phenytoin use causes gingival hyperplasia, hirsutism, and cerebellar atrophy.
Key Clinical Considerations
Therapeutic drug monitoring is essential for phenytoin, carbamazepine, and valproate due to their narrow therapeutic indices and nonlinear pharmacokinetics. Many AEDs induce or inhibit hepatic drug-metabolizing enzymes, leading to significant interactions with oral contraceptives, anticoagulants, and other medications. Pregnancy presents particular challenges, as valproate is contraindicated and lamotrigine levels decline due to increased clearance. Abrupt discontinuation of AEDs can precipitate status epilepticus and must be avoided.
Conclusion
Antiepileptic drug therapy requires careful matching of drug properties to seizure type, patient characteristics, and comorbidities. Broad-spectrum agents are preferred when the seizure type is unclear, while narrow-spectrum agents are effective for focal epilepsies. Individualized therapy, therapeutic drug monitoring, and attention to adverse effects and interactions optimize outcomes for patients living with epilepsy.
